Gilead Files Once-daily Integrase Inhibitor Elvitegravir With FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Part of the Quad combination product, stand-alone elvitegravir could open up the integrase inhibitor market. In a study supporting the single-agent NDA, once-daily elvitegravir proved comparable to Merck’s twice-daily blockbuster Isentress, the only commercially available integrase inhibitor.
You may also be interested in...
It’s Not Just Dosing: Stribild’s Side Effect Profile Could Give It An Edge In HIV Market
Gilead has priced its new 4-in-1 HIV treatment, more commonly referred to as Quad, slightly above the only other integrase inhibitor-based regimen on the market, Merck’s Isentress, but at a 35% premium to its own three-drug combo product, Atripla.
The New Quad: FDA Approves Gilead’s 4-In-1 HIV Pill Stribild
With cost concerns already arising, the sponsor says it is working to ensure the drug is covered by state AIDS Drug Assistance Programs.
Profile Of Viiv’s Unboosted Dolutegravir Emerges With First Phase III Results
Viiv Healthcare/Shionogi’s once-daily, unboosted integrase inhibitor dolutegravir is efficacious and well-tolerated in the first of four Phase III HIV trials to report, a study of treatment-naïve patients. Drug poses a competitive threat to Merck’s blockbuster Isentress and Gilead’s elvitegravir, part of the four-in-one “Quad” pill.